CN104817575A - Compound, its extraction method, pharmaceutical composition containing the same and application thereof - Google Patents
Compound, its extraction method, pharmaceutical composition containing the same and application thereof Download PDFInfo
- Publication number
- CN104817575A CN104817575A CN201510108820.7A CN201510108820A CN104817575A CN 104817575 A CN104817575 A CN 104817575A CN 201510108820 A CN201510108820 A CN 201510108820A CN 104817575 A CN104817575 A CN 104817575A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- changchun
- compound
- agent
- spring alkali
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 36
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 36
- 238000000605 extraction Methods 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 7
- 239000000126 substance Substances 0.000 claims abstract description 7
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 6
- 239000003513 alkali Substances 0.000 claims description 42
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- 241000863480 Vinca Species 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 11
- -1 thinner Substances 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 8
- 230000037396 body weight Effects 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 239000002026 chloroform extract Substances 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000004809 thin layer chromatography Methods 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000004440 column chromatography Methods 0.000 claims description 5
- 239000003981 vehicle Substances 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000013355 food flavoring agent Nutrition 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- 238000004945 emulsification Methods 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 230000000887 hydrating effect Effects 0.000 claims description 3
- 239000007951 isotonicity adjuster Substances 0.000 claims description 3
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 3
- 229920003023 plastic Polymers 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 229910052710 silicon Inorganic materials 0.000 claims description 3
- 239000010703 silicon Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000000375 suspending agent Substances 0.000 claims description 3
- 230000008719 thickening Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 239000003826 tablet Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 2
- XDFNWJDGWJVGGN-UHFFFAOYSA-N 2-(2,7-dichloro-3,6-dihydroxy-9h-xanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C21 XDFNWJDGWJVGGN-UHFFFAOYSA-N 0.000 description 2
- 241000208327 Apocynaceae Species 0.000 description 2
- 240000001829 Catharanthus roseus Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000208328 Catharanthus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000001142 circular dichroism spectrum Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000001896 rotating frame Overhauser effect spectroscopy Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
Abstract
The embodiment of the invention discloses a compound, which has a chemical structural formula as shown in the specification. The compound is called cathachunine. At the same time, the invention also provides an extraction method of the compound, a pharmaceutical composition containing the compound and application of the compound and the pharmaceutical composition in preparation of antitumor drugs. (chemical structural formula).
Description
Technical field
The present invention relates to a kind of compound, the natural compounds particularly extracted from plant Vinca, the extracting method of this compound, the pharmaceutical composition comprising this compound and this compound and pharmaceutical composition are for the preparation of the purposes in antitumor drug.
Background technology
Tumour is one of major reason causing human death.Develop into today in industrial society, the diseases such as liver cancer, mammary cancer, lung cancer have had a strong impact on the healthy living level of the people.Visible prevention and therapy tumour is very critical.Chemotherapy is a kind of effective means for the treatment of tumour, and tumor chemotherapeutic drug conventional clinically at present has tens kinds, effectively extends the life-span of the mankind, but the antitumor drug of synthesis, and toxic side effect is large, seriously limits the performance of the curative effect of these medicines.Chinese medicine and natural drug are the great wealth of China, and it has the features such as toxic side effect is little, so seeking antitumor medicine is the effective way addressed these problems from Chinese medicine and natural drug.
Vinca Catharanthus roseus (L.) G.Don is the herb of Apocynaceae (Apocynaceae) Vinca (Catharanthus) plant Vinca, yellow Vinca, another name Herba amaranthi tricoloris, life spring, four Shi Chun etc.Vinca originates in East Coast of Africa and american torrid zone area, and extensively cultivate in subtropical and tropical zones at present, China's Lingnan area and Jiangsu and Zhejiang Provinces one are with all has cultivation.The Vinca property of medicine is bitter, cold, and poisonous, tool detoxicating and fighting cancer, effect of the flat liver of heat-clearing, cures mainly the illnesss such as multiple cancerous swelling, hypertension, carbuncle sore tumefacting virus and scald.Modern pharmacological research shows, Vinca tool is antitumor, hypotensive, reducing blood-fat, hypoglycemic and expand the effect such as blood vessel.
Summary of the invention
The present inventor extracts and obtains compound Changchun spring alkali (cathachunine) from the dry herb of Vinca, and the present inventor has also found that above-mentioned Changchun spring alkali (cathachunine) can be used for antitumor.Present invention also offers the pharmaceutical composition comprising above-mentioned Changchun spring alkali (cathachunine), and this pharmaceutical composition is for the preparation of the purposes in antitumor drug.Concrete technical scheme is as follows:
A first aspect of the present invention provides compound, and the chemical structural formula of this compound is as follows:
Above-claimed cpd is called Changchun spring alkali (cathachunine).
A second aspect of the present invention provides the extracting method of above-claimed cpd Changchun spring alkali, comprises the following steps:
(1) extract: by dry for Vinca herb, pulverize, with aqueous ethanolic solution refluxing extraction, obtain medicinal extract, adjust pH to 2-3 with HCl solution after thin up, filter, obtain filtrate and filter residue, filtrate adds NH
3h
2o adjusts pH to 9-10, with chloroform extraction, obtains chloroform extract;
(2) be separated: by above-mentioned chloroform extract applying silicon plastic column chromatography, with the chloroform-methanol system gradient elution of volume 100:1 to 2:1, thin-layer chromatography detects, collection obtains the flow point containing Changchun spring alkali (cathachunine), again through ODS column chromatogram chromatography, take volume ratio as the methanol-water system elutions of 20:80, thin-layer chromatography detects, and obtains the sterling of described Changchun spring alkali cathachunine.
In a preferred embodiment of a second aspect of the present invention, above-mentionedly obtain medicinal extract with aqueous ethanolic solution refluxing extraction, be specially: with 95% alcohol reflux 2-4 time, each 2-3 hour, extracting solution is evaporated to medicinal extract.
A third aspect of the present invention provides a kind of pharmaceutical composition, and this pharmaceutical composition comprises above-mentioned compound Changchun spring alkali (cathachunine) and optional pharmaceutically acceptable carrier or vehicle.
In a preferred embodiment of third aspect present invention, based on the gross weight of described pharmaceutical composition, the content of described compound Changchun spring alkali (cathachunine) is 1-99%, is preferably 20-80%, is more preferably 40-60%.
In another preferred embodiment of third aspect present invention, described pharmaceutically acceptable carrier or vehicle are selected from solvent, thinner, dispersion agent, suspending agent, tensio-active agent, isotonic agent, thickening material, emulsifying agent, sanitas, tackiness agent, lubricant, stablizer, hydrating agents, emulsification accelerator, buffer reagent, absorption agent, tinting material, flavouring agent, sweeting agent, ion-exchanger, releasing agent, coating agent, correctives and antioxidant.
In another preferred embodiment of third aspect present invention, the formulation of described pharmaceutical composition is tablet, capsule, pulvis, granule, lozenge, pill, solution, suspensoid, emulsion, syrup, powder, granula subtilis, pilule, elixir, injection, medicinal drops, ointment, lotion, gelifying agent, emulsifiable paste, sprays, suppository or patch.
A fourth aspect of the present invention provides above-mentioned compound Changchun spring alkali (cathachunine) or above-mentioned pharmaceutical composition for the preparation of the purposes in antitumor drug.
In a preferred embodiment of fourth aspect present invention, every per daily dose that described medicine gives object in need counts 0.01-1000mg/kg body weight with compound Changchun spring alkali, is preferably 0.1-100mg/kg body weight, is more preferably 1-100mg/kg body weight.
The present inventor extracts and obtains compound Changchun spring alkali (cathachunine) from the dry herb of Vinca, and this compound is white powder, [α] 20D+22.5 (c 0.2, CHCl
3); By electron spray(ES) ion massspectrum signal m/z:709.33605 [M+H]
+, calculate that its molecular formula is C
41h
48n
4o
7; And pass through
1h and
13c nucleus magnetic resonance and UV spectrum determine its structure.
As used herein, term " ODS post " refers to octadecylsilane post.
The routine techniques in formulation art can be adopted, the effective constituent of the raw material of pharmaceutical composition of the present invention is obtained by extracting method according to the present invention, with one or more of pharmaceutically acceptable carrier or mixed with excipients, then form required formulation, prepare pharmaceutical composition of the present invention.
As used herein, " pharmacy is acceptable " represents when not having tangible toxic action with during usual dosage use, thus by government or the international organization suitable with it approval or can be approved for animal, more specifically to people, or be registered in pharmacopeia.
" pharmaceutically acceptable carrier or vehicle " available in pharmaceutical composition of the present invention can be the carrier of any routine in field of pharmaceutical preparations, and the selection of specific support will depend on the administering mode or disease type and state that are used for the treatment of particular patient.For the preparation method of the said synthetic processes of specific administration pattern completely in the ken of pharmaceutical field technician.Such as, the solvent of pharmaceutical field routine, thinner, dispersion agent, suspending agent, tensio-active agent, isotonic agent, thickening material, emulsifying agent, tackiness agent, lubricant, stablizer, hydrating agents, emulsification accelerator, buffer reagent, absorption agent, tinting material, ion-exchanger, releasing agent, coating agent, correctives and antioxidant etc. can be comprised as pharmaceutically acceptable carrier.If desired, flavouring agent, preservative and sweetener etc. can also be added in pharmaceutical composition.
As used herein, term " pharmaceutical composition " has its general sense.In addition, " pharmaceutical composition " of the present invention can also exist with forms such as healthcare products, functional foodstuff, food, foodstuff additive or provide.The routine techniques of pharmacy field particularly in formulation art can be adopted, the effective constituent of the raw material of pharmaceutical composition of the present invention is obtained by extraction separation and purification means conventional in pharmaceutical production, optionally mix with one or more of pharmaceutically acceptable carrier, then form required formulation, prepare pharmaceutical composition of the present invention.According to pharmaceutical composition of the present invention, it is the pharmaceutical preparation going for oral administration, parenteral admin or topical, topical administration.Pharmaceutical composition of the present invention can make the various ways such as tablet, pulvis, granule, capsule, oral liquid.The medicine of above-mentioned various formulation all can be prepared according to the ordinary method of pharmaceutical field.Specifically, according to pharmaceutical composition of the present invention, described pharmaceutical dosage form includes but not limited to: tablet, capsule, granule, pulvis, injection liquid, injectable powder, transdermal patch, ointment, gelifying agent, suppository, oral liquid, oral administration mixed suspension, injectable emulsion, Orally taken emulsion etc., slow releasing tablet, controlled release tablet.The medicine of above-mentioned various formulation all can be prepared according to the ordinary method of pharmaceutical field.
Such as tablet, pill, hard or soft capsule, solution, suspensoid, emulsion, syrup, powder, pulvis, granula subtilis, granule, pilule, elixir etc. can be comprised for Orally administered formulation, be not limited to this.Except activeconstituents, these preparations also can comprise thinner (such as lactose, dextrose, sucrose, mannitol, Sorbitol Powder, Mierocrystalline cellulose and glycine), lubricant (such as silicon-dioxide, talcum, stearic acid or its magnesium salts, calcium salt and polyoxyethylene glycol).Tablet also can comprise tackiness agent, such as neusilin, starch paste, gelatin, tragacanth, methylcellulose gum, Xylo-Mucine and polyvinylpyrrolidine.If desired, it also can comprise medicinal additive, such as disintegrating agent (as starch, agar, Lalgine or its sodium salt), absorption agent, tinting material, flavouring agent, sweeting agent etc.Tablet can according to the method preparation of conventional mixing, granulation or dressing.
Formulation for using outside enteron aisle can comprise such as injection, medicinal drops, ointment, lotion, gelifying agent, emulsifiable paste, sprays, suspensoid, emulsion, suppository, patch etc., is not limited to this.
According to pharmaceutical composition of the present disclosure can oral or non-bowel such as per rectum, through local, through skin, through intravenously, through intramuscular, through intraperitoneal or through subcutaneous administration.
The acceptable dosage of pharmacy of activeconstituents, i.e. application dosage, can change according to the judgement of the severity of the age of object to be treated, sex and body weight, disease specific to be treated or pathological state, disease or pathological state, route of administration and diagnosis person.Consider that these factor determination application dosages are in the horizontal extent of those skilled in the art.General dosage can be 0.01-1000mg/kg/ day, is preferably 0.1-100mg/kg/ day, is more preferably 1-100mg/kg/ day.But the scope of the present disclosure is limited to described application dosage never in any form.
Accompanying drawing explanation
In order to be illustrated more clearly in the embodiment of the present invention or technical scheme of the prior art, be briefly described to the accompanying drawing used required in embodiment or description of the prior art below, apparently, accompanying drawing in the following describes is only some embodiments of the present invention, for those of ordinary skill in the art, under the prerequisite not paying creative work, other accompanying drawing can also be obtained according to these accompanying drawings.
Fig. 1 is the fluorescence intensity after the Changchun spring alkali effect HL-60 cell 48h under different concns;
The comparison diagram of the ROS of 48h after Changchun spring alkali effect HL-60 cell under Fig. 2 different concns.
Embodiment
Below in conjunction with the accompanying drawing in the embodiment of the present invention, be clearly and completely described the technical scheme in the embodiment of the present invention, obviously, described embodiment is only the present invention's part embodiment, instead of whole embodiments.Based on the embodiment in the present invention, those of ordinary skill in the art, not making the every other embodiment obtained under creative work prerequisite, belong to the scope of protection of the invention.
The extraction in embodiment 1 compound Changchun spring alkali (cathachunine) and sign
1, instrument and material
X-5 type micro melting point apparatus (Tyke, Beijing instrument company); Jasco FT/IR-480Plus FourierTransform infrared spectrometer (Japan Spectroscopy Corporation); Jasco V-550 UV/visible spectrophotometer (Japan Spectroscopy Corporation); Bruker AV-400MHz nuclear magnetic resonance analyser, TMS is interior mark (German Bruker company); Thermo Finnigan LCQ Advantage MAX mass spectrograph (Thermo company of the U.S.); Dionex analysis mode high performance liquid chromatograph (Dionex company of the U.S.); Cosmosil C-18 chromatographic column (250mm × 4.6mm, 5 μm); Vari an preparative high performance liquid chromatography instrument (Varian company of the U.S.); Column chromatography is with silica gel (Haiyang Chemical Plant, Qingdao); Silica GF254 thin layer precoated plate (Yantai chemical industry institute); Sephadex LH-20 (Pharmacia company); ODS column chromatography material (German Merck company); Agents useful for same is analytical pure and chromatographically pure.
Vinca medicinal material picks up from Haikou City, Hainan Province, is accredited as Vinca (Catharanthus roseus (L.) G.Don) herb by Tianjin University Of Traditional Chinese Medicine doctor Wang Chunhua.Herbarium (No.2012CH0014) deposits in modern Chinese herbal medicine laboratory, Tianjin University Of Traditional Chinese Medicine strand.
2, the extraction in Changchun spring alkali (cathachunine)
The dry herb 3kg of Vinca, pulverizes, and with 95% ethanol 20L refluxing extraction 3 times, each 2 hours, extracting solution was evaporated to medicinal extract 500g, and adjust pH to 2-3 with HCl solution after thin up, filter, obtain filtrate and filter residue, filtrate adds NH
3h
2o adjusts pH to 9-10, with chloroform extraction, obtains chloroform extract, obtains crude product 115g after concentrating under reduced pressure; By above-mentioned chloroform extract applying silicon plastic column chromatography, with the chloroform methanol system gradient elution of volume 100:1 to 2:1, thin-layer chromatography detects, collection obtains the flow point 20g containing Changchun spring alkali (cathachunine), again through ODS column chromatogram chromatography, take volume ratio as the methanol-water system elutions of 20:80, thin-layer chromatography detects, and obtains the sterling 40mg of Changchun spring alkali (cathachunine).
3, characterize
Compound Changchun spring alkali (cathachunine): white powder, [α] 20D+22.5 (c 0.2, CHCl
3); By electron spray(ES) ion massspectrum signal m/z:709.33605 [M+H]
+, calculate that its molecular formula is C
41h
48n
4o
7; UV spectrum has strong absorption at 220nm and 260nm, illustrates that this compound has indole ring structures feature; Infrared spectra is at 3452cm
-1, 1737cm
-1, 1688cm
-1there is absorption peak at place, points out this compound to contain hydroxyl, carbonyl and amide group.
1four fragrant Hydrogen Proton signal [δ 7.53 (1H on H nuclear magnetic resonance spectrum display indole ring, d, J=7.6Hz, 7.16 (1H, m), 7.13 (1H, m) He 7.11 (1H, d, J=7.6Hz)] and four indoline rings on feature Hydrogen Proton signal [δ 6.52 (1H, s), 6.08 (1H, s), 5.67 (1H, dd, J=9.6,4.0Hz) and 5.46 (1H, d, J=9.6Hz)], above nuclear magnetic data points out this compound to be vinealeucoblastine(VLB) (VLB) type alkaloid.Can see that H-3 ' a (δ 3.99)/H-5 ' b (δ 2.99)/H-14 ' (δ 1.54) and C-18 (δ 179.0) has relevant from HMBC spectrum, illustrate that C-20 with N-4 is connected in amido linkage mode, the absolute steric configuration of Changchun spring alkali can be determined in conjunction with ROESY spectrum and CD spectrum.
1h and
13c nuclear magnetic resonance data can the chemical structural formula in deterministic compound Changchun spring alkali (cathachunine) from above-mentioned sign in table 1..
Table 1 Changchun spring alkali (cathachunine)
1h and
13c nuclear magnetic resonance data
1h and
13c nuclear magnetic data records respectively under 400MHz and 100MHz, and J is coupling constant.
The cytotoxic activity test in embodiment 2 Changchun spring alkali (Cathachunine)
1, experiment material
1.1 given the test agent
Changchun spring alkali (cathachunine) of embodiment 1 being extracted is with after DMSO (Merck) dissolving, add PBS (-) and be made into the solution of 100 μMs/ml or uniform mixed solution, then dilute with the PBS (-) containing DMSO.
1.2 cell strain
HL-60 (human leukemia cell, American Type Culture Collection, (ATCC))
K562 (human leukemia cell, American Type Culture Collection, (ATCC))
EA.hy926 (human endothelial cell, American Type Culture Collection, (ATCC))
1.3 nutrient solution
PRMI1640 (Gibco company of the U.S.)+15%NBS (Gibco company of the U.S.)+dual anti-(HyClone company of the U.S.)
1.4 other materials
WST-1 cell proliferation and the full-automatic microplate reader of toxicity test bag (Beyotime institute of biotechnology, China): (BioTek, U.S.A.), import 96 well culture plate etc.
2, experimental technique
Cell survival rate experiment adopts WST-1 cell proliferation and toxicity test bag, adopts the Standard operation procedure SOP of this experiment bag to carry out.The 96 every holes of orifice plate add the cell suspension that concentration is 4-6 × 104/ml, are placed in 37 DEG C, 5%CO2 incubator.Every hole adds the WST solution (comprising the medium of 100 μ l) of 10 μ l, after cultivating 2h, surveys the OD value under 450nm under microplate reader.
3, test-results
The results are shown in Table 2. result display Changchun spring alkali, to human leukemia cell line HL-60 and K562, there is significant cytotoxic activity, to human endothelial cell EAhy926, there is faint cytotoxicity.
The cytotoxicity of table 2. Changchun spring alkali
Embodiment 3 Changchun spring alkali (Cathachunine) is to the impact of active oxygen in tumour cell (Reactive oxygenspecies, ROS) level
1, experiment material
1.1 given the test agent
Changchun spring alkali (cathachunine) adds PBS (-) and is made into the solution of 100 μMs/ml or uniform mixed solution, then dilute with the PBS (-) containing DMSO after dissolving with DMSO (Merck).
1.2 cell strain
HL-60 (human leukemia cell, American Type Culture Collection, (ATCC))
1.3 nutrient solution
PRMI1640 (Gibco company of the U.S.)+15%NBS (Gibco company of the U.S.)+dual anti-(HyClone company of the U.S.)
1.4 other materials
Fluorescent microscope XSP-BM21AY (Shanghai opticinstrument six factory)
2, test method
Common fluorescent probe DCFH-DA, can become the DCFH not having fluorescence by deacetylation in cell, and in time having ROS in cell, DCFH can continue to be oxidized to the DCF with fluorescence, and his fluorescence represents the level of intracellular ROS.This experiment adopts DCFH-DA to have rated Changchun spring alkali (cathachunine) and generates the intracellular ROS of HL-60.Concrete test method is: HL-60 cells rinsed with PBS once, adds DCFH-DA, preserves 30 minutes for 37 DEG C in the dark.Then by cell washing twice, be kept in 1ml substratum.The generation of ROS adopt fluorescent microscope 488 and 530nm excite with emission wavelength under measure respectively.Fluorescence intensity adopt fluorescence microplate reader further 488 and 525nm excite with emission wavelength under analyze and obtain.
3, test-results, as Fig. 1 and Fig. 2.
In Fig. 1 a-d tetra-little figure show respectively Changchun spring alkali respectively under concentration 1,3,10,30 μMs of concentration on the impact producing ROS level in HL-60 cell.It is higher that phosphor dot represents its ROS level more; In Fig. 2 with bar graph form describe equally Changchun spring alkali in concentration 1,3,10,30 μMs of situations on HL-60 produce ROS level and affect.Above two figure all describe compound Changchun spring alkali (cathachunine) under the concentration of 30 μMs, after cultivating 48h, can significantly improve the generation of the intracellular ROS of HL-60.
Embodiment 4: the tablet preparing pharmaceutical composition of the present invention
Mix above composition according to common method and make tablet.
Embodiment 5: the capsule preparing pharmaceutical composition of the present invention
Mix above composition according to common method and load in gelatine capsule.
The foregoing is only preferred embodiment of the present invention, be not intended to limit protection scope of the present invention.All any amendments done within the spirit and principles in the present invention, equivalent replacement, improvement etc., be all included in protection scope of the present invention.
Claims (10)
1. a compound, is characterized in that, chemical structural formula is as follows:
Described compound is called Changchun spring alkali.
2. an extracting method for compound Changchun according to claim 1 spring alkali, is characterized in that, comprise the following steps:
(1) extract: by dry for Vinca herb, pulverize, with aqueous ethanolic solution refluxing extraction, obtain medicinal extract, adjust pH to 2-3 with HCl solution after thin up, filter, obtain filtrate and filter residue, filtrate adds NH
3h
2o adjusts pH to 9-10, with chloroform extraction, obtains chloroform extract;
(2) be separated: by above-mentioned chloroform extract applying silicon plastic column chromatography, with the chloroform-methanol system gradient elution of volume 100:1 to 2:1, thin-layer chromatography detects, collect the flow point obtained containing Changchun spring alkali, again through ODS column chromatogram chromatography, take volume ratio as the methanol-water system elutions of 20:80, thin-layer chromatography detects, and obtains the sterling of described Changchun spring alkali.
3. method as claimed in claim 2, is characterized in that, describedly obtains medicinal extract with aqueous ethanolic solution refluxing extraction, is specially: with 95% alcohol reflux 2-4 time, each 2-3 hour, extracting solution is evaporated to medicinal extract.
4. a pharmaceutical composition, is characterized in that, this pharmaceutical composition comprises compound Changchun according to claim 1 spring alkali and optional pharmaceutically acceptable carrier or vehicle.
5. pharmaceutical composition as claimed in claim 4, it is characterized in that, based on the gross weight of described pharmaceutical composition, the content of described compound Changchun spring alkali is 1-99%.
6. pharmaceutical composition as claimed in claim 5, it is characterized in that, based on the gross weight of described pharmaceutical composition, the content of described compound Changchun spring alkali is 20-80%.
7. pharmaceutical composition as claimed in claim 6, it is characterized in that, based on the gross weight of described pharmaceutical composition, the content of described compound Changchun spring alkali is 40-60%.
8. pharmaceutical composition as claimed in claim 4, it is characterized in that, described pharmaceutically acceptable carrier or vehicle are selected from solvent, thinner, dispersion agent, suspending agent, tensio-active agent, isotonic agent, thickening material, emulsifying agent, sanitas, tackiness agent, lubricant, stablizer, hydrating agents, emulsification accelerator, buffer reagent, absorption agent, tinting material, flavouring agent, sweeting agent, ion-exchanger, releasing agent, coating agent, correctives and antioxidant.
9. compound Changchun spring alkali as claimed in claim 1 or pharmaceutical composition according to claim 3 are for the preparation of the purposes in antitumor drug.
10. purposes as claimed in claim 9, is characterized in that, every per daily dose that described medicine gives object in need is counted 0.01-1000mg/kg body weight with compound Changchun spring alkali, be preferably 0.1-100mg/kg body weight, be more preferably 1-100mg/kg body weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510108820.7A CN104817575B (en) | 2015-03-12 | 2015-03-12 | Compound, its extraction method, pharmaceutical composition containing the same and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510108820.7A CN104817575B (en) | 2015-03-12 | 2015-03-12 | Compound, its extraction method, pharmaceutical composition containing the same and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104817575A true CN104817575A (en) | 2015-08-05 |
| CN104817575B CN104817575B (en) | 2017-02-01 |
Family
ID=53728074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510108820.7A Active CN104817575B (en) | 2015-03-12 | 2015-03-12 | Compound, its extraction method, pharmaceutical composition containing the same and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104817575B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007098091A2 (en) * | 2006-02-17 | 2007-08-30 | Novacea, Inc. | Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs |
| CN101628916A (en) * | 2009-08-04 | 2010-01-20 | 华中科技大学 | Cathearanthus alkaloid |
-
2015
- 2015-03-12 CN CN201510108820.7A patent/CN104817575B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007098091A2 (en) * | 2006-02-17 | 2007-08-30 | Novacea, Inc. | Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs |
| CN101628916A (en) * | 2009-08-04 | 2010-01-20 | 华中科技大学 | Cathearanthus alkaloid |
Non-Patent Citations (2)
| Title |
|---|
| MARTIN E. KUEHNE，等: "Syntheses and biological evaluation of vinblastine congeners", 《ORG.BIOMOL.CHEM.》 * |
| 张爱红，等: "长春花生物碱类衍生物及靶向前药研究进展", 《中国新药杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104817575B (en) | 2017-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1800685B1 (en) | Steroidal saponin pharmaceutical composition, its preparation method and use | |
| JPH02311496A (en) | Dolastatin 15 and use thereof | |
| CN107986951B (en) | Novel topoisomerase I inhibitor, pharmaceutical composition thereof, preparation method and application thereof | |
| CN101502585B (en) | Chinese red pepper plant extract as well as preparation method and application thereof | |
| Georgieva et al. | Antiproliferative and antitumour activity of saponins from Astragalus glycyphyllos on myeloid Graffi tumour | |
| WO2016107579A1 (en) | Preparation and application of flavonol as brain-targeting synergist | |
| CN104370871B (en) | The mouth diphenylene ketone oxide class separated from Swertia punicea Hemsl. and the application of suppression hepatitis B virus | |
| EP3156058B1 (en) | Anti-tumor pharmaceutical application of pentacyclic triterpene saponin compounds of szechuan melandium root | |
| US7138428B2 (en) | Compounds isolated from gamboge resin having activity in inhibiting the growth of tumor/cancer cells and pharmaceutical compositions comprising the same | |
| Luo et al. | Isolation, synthesis and bioactivity evaluation of isoquinoline alkaloids from Corydalis hendersonii Hemsl. against gastric cancer in vitro and in vivo | |
| TW201000112A (en) | Use of dehydrosulphurenic acid for inhibiting the growth of cancer cells | |
| WO2017092230A1 (en) | Biflavone compound and uses thereof for treating cancers and preparing drugs | |
| CN102908340B (en) | Isolicoflavonol-containing antitumor drug and application thereof | |
| CN108659089B (en) | Sterol compound with antioxidant effect and application thereof in preparation of medicines | |
| CN109320409A (en) | A kind of preparation method and applications with antimycotic and anti-tumor activity anthraquinone dimer class compound | |
| CN104817575A (en) | Compound, its extraction method, pharmaceutical composition containing the same and application thereof | |
| CN111529515B (en) | Application of 12, 15-dioxo-alpha-cnidiene in pharmacy | |
| CN107674054A (en) | The miscellaneous terpene compound of a kind of new skeleton, its preparation method, pharmaceutical composition and antitumor application thereof | |
| CN107286123A (en) | A kind of preparation method of dibenzofuran class compound and application | |
| CN102670670A (en) | Preparation method of ginkgo dipyridolum injection with high content of ginkgo terpene lactones | |
| CN102295678B (en) | Purpose of triterpenoid-saponin compound extracted form anemone taipaiensis | |
| CN106138076B (en) | Flavonoid glycoside dimer and its preparation method and application | |
| CN108358947A (en) | A kind of caged xanthene ketone compounds and its preparation method and application | |
| CN102229640B (en) | Application of triterpenoid saponins compound extracted from anemone taipaiensis | |
| CN107007600B (en) | Antitumor pharmaceutical composition with lipoyunaconitine as active ingredient and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |